QualityStocks
would like to highlight PLC Systems Inc. (OTCBB: PLCSF). The company,
headquartered in
In the
company’s news yesterday,
PLC Systems, Inc., announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy® and RenalGuard System™ in the prevention of Contrast-Induced Nephropathy (CIN). This is an important step in the process to secure regulatory approval by the U.S. Food and Drug Administration (FDA) for the distribution of RenalGuard® in the United States.
]The first patient was enrolled by Dr. Michael Kim, Director of the Coronary Care Unit at Mount Sinai Hospital in New York, New York.
"RenalGuard offers us the potential for a method to reduce the incidence of CIN while allowing me as an interventional cardiologist to focus on the catheterization without having to worry that the contrast may be damaging the patient's kidney," said Dr. Kim.
Dr. Roxana Mehran, Director of Interventional Cardiovascular Research at Mount Sinai and one of the three Principal Investigators in the CIN-RG Trial, said, "I am very excited to have this trial underway and overjoyed that Mount Sinai could enroll the first patient. CIN remains a real problem for patients undergoing cardiac catheterizations. RenalGuard trials give us the opportunity to examine a tool that could significantly reduce the incidence of CIN in our at-risk patients."
Mark R.
Tauscher, President and Chief Executive Officer of PLC, said, "We're very
pleased to be able to move forward with our U.S. pivotal trial, starting with
many of the hospitals that had participated in our earlier trial. The team at
Mt. Sinai, particularly Dr. Mehran, has led the way in our understanding of
CIN, and we are honored that they would choose to participate in the CIN-RG
study. Using lessons learned from the clinical trials of RenalGuard in Europe
as well as other clinical developments since 2008, we made slight modifications
to our original trial protocol that we believe will make it more robust. This
is a very important step on our path forward to seeking FDA approval to market
RenalGuard in the U.S."
PLC's U.S. pivotal study is under the supervision of Principal Investigators Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School, Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine and Dr. Mehran. It is designed as an adaptive, randomized controlled trial at up to 30 sites in the U.S. Enrollment in the trial will include at least 326 patients and potentially up to 652 patients, depending upon the outcome of a sample size re-estimation after 163 patients. The sample size re-estimation, often used in adaptive trials, enables investigators to ensure that the trial is sufficiently powered so that the final results are statistically meaningful.
PLC's U.S. study builds upon two clinical trials by independent clinical investigators in Europe, both of which showed significant reductions in incident rates of CIN in at-risk patients through the use of RenalGuard compared to the current standard of care.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking
Statement:
This release
may contain forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All forward-looking statements are inherently
uncertain as they are based on current expectations and assumptions concerning
future events or future performance of the company. Readers are cautioned not
to place undue reliance on these forward-looking statements, which are only
predictions and speak only as of the date hereof. Risks and uncertainties
applicable to the company and its business could cause the company's actual
results to differ materially from those indicated in any forward-looking
statements.
